Richard J. Dimelow

Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial.

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial.

Journal: Arthritis care & research

Published: March 14, 2025

Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.

Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.

Journal: Clinical pharmacokinetics

Published: September 03, 2024

Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus.

Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus.

Journal: British journal of clinical pharmacology

Published: April 16, 2024

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Journal: Rheumatology (Oxford, England)

Published: December 01, 2023

Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab.

Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: July 21, 2023

Population model-based analysis of the memory B-cell response following belimumab therapy in the treatment of systemic lupus erythematosus.

Population model-based analysis of the memory B-cell response following belimumab therapy in the treatment of systemic lupus erythematosus.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 29, 2022

Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers.

Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers.

Journal: British journal of clinical pharmacology

Published: May 28, 2021

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.

Journal: Arthritis research & therapy

Published: May 14, 2021

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.

Journal: Clinical pharmacology in drug development

Published: July 27, 2020

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers.

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers.

Journal: Drugs in R&D

Published: July 29, 2018

Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts.

Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts.

Journal: Computer methods and programs in biomedicine

Published: December 21, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026